Carbiotix (CRBX) Q3 2025 earnings summary

Executive summary

• Net sales for Q3 2025 reached 340,045 SEK, a significant increase from 90,503 SEK in Q3 2024.

• Net loss after financial items improved to -3,120,401 SEK from -4,058,093 SEK year-over-year.

• The company is transitioning from project and proof-of-concept phases to commercial agreements and growth, focusing on NutraCycle and refining sales and lab report offerings.

• Streamlined operations and team expansion have improved project success rates and responsiveness to customer feedback.

• Ongoing efforts to secure new projects and license agreements, with the first license deal expected by early 2026.

Financial highlights

• Q3 net sales: 340,045 SEK (Q3 2024: 90,503 SEK).

• Q3 net loss after financial items: -3,120,401 SEK (Q3 2024: -4,058,093 SEK).

• EPS for Q3: -0.63 SEK (Q3 2024: -1.08 SEK).

• Cash and cash equivalents at period end: 605,294 SEK (Q3 2024: 5,044,379 SEK).

• Operating cash flow for the nine months: -10,630,172 SEK (2024: -16,161,579 SEK).

Outlook and guidance

• Anticipates improved efficiency and faster deal cycles for future license agreements as experience grows.

• Aims to secure multiple license agreements in 2026, with ongoing process optimization to support scalable growth.

• Focus on converting high-potential customer projects to development agreements and increasing market penetration for NutraCycle.

• Strategic shift to private ownership to facilitate capital access and operational focus.